<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PANTOPRAZOLE SODIUM</span><br/>(pan-to'pra-zole)<br/><span class="topboxtradename">Protonix, </span><span class="topboxtradename">Protonix IV<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">proton pump inhibitor</span><br/><b>Prototype: </b>Omeprazole<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>40 mg enteric coated tablets; 40 mg vial</p>
<h1><a name="action">Actions</a></h1>
<p>Gastric acid pump inhibitor; belongs to a class of antisecretory compounds. Gastric acid secretion is decreased by inhibiting
         the H<sup>+</sup>, K<sup>+</sup>-ATPase enzyme system responsible for acid production.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Specifically, suppresses gastric acid secretion by inhibiting the acid (proton H<sup>+</sup>) pump in the parietal cells.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD).</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to pantoprazole or other proton pump inhibitors (PPIs); severe hepatic insufficiency, cirrhosis.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Mild to moderate hepatic insufficiency; pregnancy (category B), lactation. Safety and effectiveness in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Erosive Esophagitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 40 mg q.d. times 816 wk <span class="rdroute">IV</span> 40 mg q.d. times 710 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not crush or break in half. Must be swallowed whole.</li>
<li>
            				Note: Therapy beyond 16 wk is not recommended.
            			
         </li>
<li>Store preferably at 20°25° C (66°77° F), but room temperature permitted.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span>
<i>Two-min infusion:</i> Reconstitute each 40 mg vial with 10 mL NS. <i>Fifteen-min infusion:</i> Reconstitute as for 2-min infusion, then further dilute with 100 mL of D5W, NS, or RL to yield 0.4 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>  Give through a dedicated line or flushed IV line before and after each dose with D5W, NS, or RL. <i>Two-min infusion:</i> Give over at least 2 min. <i>Fifteen-min infusion:</i> Infuse over 15 min at a rate of 6 mg/min (7 mL/min). Note: Protonix IV packaged with an in-line filter must be used with the provided filter. A newer formulation does not require an
                  in-line filter.
                  						  
               </p>
</td>
</tr>
</table>
<ul>
<li>Reconstituted solution may be stored for up to 2 h at 1530° C (5986° F) before further dilution. The
            diluted 100 mL solution may be stored for up to 22 h.
         </li>
</ul>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/Additive:</span> Solutions containing<b> zinc.</b>
<span class="incompattype">Y-site:</span>
<b>Midazolam.</b>
</p>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> Diarrhea, flatulence, abdominal pain. <span class="typehead">CNS:</span> Headache, insomnia. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May decrease absorption of <b>ampicillin,</b>
<span class="classification">iron salts</span>, <b>itraconazole,</b>
<b>ketoconazole;</b> increases INR with <b>warfarin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed with 77% bioavailability. <span class="typehead">Peak:</span> 2.4 h. <span class="typehead">Distribution:</span> 98% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver primarily by CYP2C19. <span class="typehead">Elimination:</span> 71% excreted in urine, 18% in feces. <span class="typehead">Half-Life:</span> 1 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for and immediately report S&amp;S of angioedema or a severe skin reaction.</li>
<li>Lab tests: Urea breath test 46 wk after completion of therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Contact physician promptly if any of the following occur: Peeling, blistering, or loosening of skin; skin rash, hives, or
            itching; swelling of the face, tongue, or lips; difficulty breathing or swallowing.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>